Showing results (981-990 of 1,491) with videos related to

Sort By:
Pageof 150
Dalton Transactions (Cambridge, England : 2003)|October 26, 2017
A trans-bidentate bis-pyridinyl ligand with a transition metal hingeNoah C Vieira, Jared A Pienkos, Colin D McMillen, et al.
MMWR. Morbidity and Mortality Weekly Report|September 30, 2021
Safety Monitoring of an Additional Dose of COVID-19 Vaccine - United States, August 12-September 19, 2021Anne M Hause, James Baggs, Julianne Gee, et al.
Journal of Rehabilitation Research and Development|July 10, 2012
How do sock ply changes affect residual-limb fluid volume in people with transtibial amputation?Joan E Sanders, Daniel S Harrison, Katheryn J Allyn, et al.
Sexually Transmitted Diseases|May 15, 2014
Impact of a routine, opt-out HIV testing program on HIV testing and case detection in North Carolina sexually transmitted disease clinicsPamela W Klein, Lynne C Messer, Evan R Myers, et al.
Cancer Gene Therapy|June 6, 2009
Dynamics of multiple myeloma tumor therapy with a recombinant measles virusD Dingli, C Offord, R Myers, et al.
Obstetrics and Gynecology|July 5, 2005
Prospective data collection of a new procedure by a specialty society: the FIBROID registryEvan R Myers, Scott Goodwin, Wendy Landow, et al.
Journal of Gerontological Nursing|November 28, 2022
Inclusive Care Practices and Policies Among Sexual and Gender Minority Older AdultsJoel G Anderson, Jason D Flatt, Ethan C Cicero, et al.
Free Radical Biology & Medicine|March 15, 2013
Redox activation of Fe(III)-thiosemicarbazones and Fe(III)-bleomycin by thioredoxin reductase: specificity of enzymatic redox centers and analysis of reactive species formation by ESR spin trappingJudith M Myers, Qing Cheng, William E Antholine, et al.
Gynecologic Oncology|February 17, 2009
Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatmentLaura J Havrilesky, Gloria Broadwater, Debra M Davis, et al.
Gynecologic Oncology|September 1, 2020
Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancerRafael Gonzalez, Laura J Havrilesky, Evan R Myers, et al.
Pageof 150